Long-term outcomes of patients with HER2-positive invasive lobular carcinoma in the ALTTO trial (BIG 2-06/NCCTG N063D [Alliance]). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.
Axillary lymph nodes pCR (apCR) versus breast pCR (bpCR): A meta-analysis involving 10,723 patients. Impact of peridiagnostic genetic counseling and germline testing on treatment decisions for ...
The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results